Henry Hsu, MD is the Founder and CEO of Allysta Pharmaceuticals. He has been engaged in ophthalmic drug development for over 10 years. He was most recently the co-founder and CEO of Altheos, Inc., where he led business development negotiations and raised over $32 million to develop a novel ROCK inhibitor for glaucoma. Prior to that, Dr. Hsu served as Chief Medical Officer (CMO) of Molecular Partners and has held various CMO and clinical research positions of increasing responsibility at CoMentis, Co-Therix, Intermune and Chiron. Dr. Hsu received his medical degree from the University of California, San Francisco.